Caroline Stokke
- Assoc. Prof.; PhD
- +47 98 68 52 14
Publications 2024
SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [177Lu]Lu-DOTATATE
J Nucl Med, 65 (5), 753-760
DOI 10.2967/jnumed.123.266843, PubMed 38548350
Do we need dosimetry for the optimization of theranostics in CNS tumors?
Neuro Oncol, 26 (Supplement_9), S242-S258
DOI 10.1093/neuonc/noae200, PubMed 39351795
The prognostic value of [18F]FDG PET/CT texture analysis prior to transplantation for unresectable colorectal liver metastases
Clin Physiol Funct Imaging (in press)
DOI 10.1111/cpf.12908, PubMed 39358976
EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials
Eur J Nucl Med Mol Imaging, 51 (5), 1268-1286
DOI 10.1007/s00259-024-06640-x, PubMed 38366197
Publications 2023
Use of ionizing radiation in a Norwegian cohort of children with congenital heart disease: imaging frequency and radiation dose for the Health Effects of Cardiac Fluoroscopy and Modern Radiotherapy in Pediatrics (HARMONIC) study
Pediatr Radiol, 53 (12), 2502-2514
DOI 10.1007/s00247-023-05774-8, PubMed 37773444
Correlations between [68Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [177Lu]Lu-DOTA-TATE
Cancers (Basel), 15 (4)
DOI 10.3390/cancers15041134, PubMed 36831477
Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update
Semin Nucl Med, 53 (3), 413-425
DOI 10.1053/j.semnuclmed.2022.12.006, PubMed 36635112
Results from an EANM survey on time estimates and personnel responsible for main tasks in molecular radiotherapy dosimetry
Eur J Nucl Med Mol Imaging, 50 (9), 2595-2604
DOI 10.1007/s00259-023-06215-2, PubMed 37129712
EANM enabling guide: how to improve the accessibility of clinical dosimetry
Eur J Nucl Med Mol Imaging, 50 (7), 1861-1868
DOI 10.1007/s00259-023-06226-z, PubMed 37086275
Correction to: EANM enabling guide: how to improve the accessibility of clinical dosimetry
Eur J Nucl Med Mol Imaging, 50 (10), 3157-3158
DOI 10.1007/s00259-023-06304-2, PubMed 37382664
Radiation safety considerations for the use of radium-224-calciumcarbonate-microparticles in patients with peritoneal metastasis
Front Med (Lausanne), 10, 1058914
DOI 10.3389/fmed.2023.1058914, PubMed 36844217
Time-Activity data fitting in molecular Radiotherapy: Methodology and pitfalls
Phys Med, 117, 103192
DOI 10.1016/j.ejmp.2023.103192, PubMed 38052710
Imaging of 212Pb in mice with a clinical SPECT/CT
EJNMMI Phys, 10 (1), 47
DOI 10.1186/s40658-023-00571-6, PubMed 37603123
Optimized SPECT Imaging of 224Ra α-Particle Therapy by 212Pb Photon Emissions
J Nucl Med, 64 (7), 1131-1137
DOI 10.2967/jnumed.122.264455, PubMed 37268424
Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation
Leukemia, 37 (10), 2107-2114
DOI 10.1038/s41375-023-01998-7, PubMed 37568010
Implementation of dosimetry for molecular radiotherapy; results from a European survey
Phys Med, 117, 103196
DOI 10.1016/j.ejmp.2023.103196, PubMed 38104033
EFOMP policy statement NO. 19: Dosimetry in nuclear medicine therapy - Molecular radiotherapy
Phys Med, 116, 103166
DOI 10.1016/j.ejmp.2023.103166, PubMed 37926641
Publications 2022
Quantitative SPECT/CT imaging of lead-212: a phantom study
EJNMMI Phys, 9 (1), 52
DOI 10.1186/s40658-022-00481-z, PubMed 35925521
Correction to: Quantitative SPECT/CT imaging of lead-212: a phantom study
EJNMMI Phys, 9 (1), 71
DOI 10.1186/s40658-022-00499-3, PubMed 36214932
Scar imaging in the dyssynchronous left ventricle: Accuracy of myocardial metabolism by positron emission tomography and function by echocardiographic strain
Int J Cardiol, 372, 122-129
DOI 10.1016/j.ijcard.2022.11.042, PubMed 36460211
FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?
Mol Imaging Biol, 24 (5), 807-817
DOI 10.1007/s11307-022-01731-3, PubMed 35486292
Is Amyloid Burden Measured by 18F-Flutemetamol PET Associated with Progression in Clinical Alzheimer's Disease?
J Alzheimers Dis, 85 (1), 197-205
DOI 10.3233/JAD-215046, PubMed 34776444
Evaluation of semi-quantitative measures of 18F-flutemetamol PET for the clinical diagnosis of Alzheimer's disease
Quant Imaging Med Surg, 12 (1), 493-509
DOI 10.21037/qims-21-188, PubMed 34993096
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
Eur J Nucl Med Mol Imaging, 49 (6), 1778-1809
DOI 10.1007/s00259-022-05727-7, PubMed 35284969
Radionuclides for Targeted Therapy: Physical Properties
Molecules, 27 (17)
DOI 10.3390/molecules27175429, PubMed 36080198
Comparison of [18F]fluciclovine and [18F]FDG PET/CT in Newly Diagnosed Multiple Myeloma Patients
Mol Imaging Biol, 24 (5), 842-851
DOI 10.1007/s11307-022-01734-0, PubMed 35501622
Publications 2021
Myelosuppression in patients treated with 177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable
Acta Oncol, 60 (11), 1481-1488
DOI 10.1080/0284186X.2021.1959635, PubMed 34425735
EANM dosimetry committee series on standard operational procedures: a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres
EJNMMI Phys, 8 (1), 77
DOI 10.1186/s40658-021-00394-3, PubMed 34767102
Left ventricular regional glucose metabolism in combination with septal scar extent identifies CRT responders
Eur J Nucl Med Mol Imaging, 48 (8), 2437-2446
DOI 10.1007/s00259-020-05161-7, PubMed 33416956
Publications 2020
EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131I mIBG treatment of neuroendocrine tumours
EJNMMI Phys, 7 (1), 15
DOI 10.1186/s40658-020-0282-7, PubMed 32144574
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma
Blood Adv, 4 (17), 4091-4101
DOI 10.1182/bloodadvances.2020002583, PubMed 32877524
Regional myocardial work by cardiac magnetic resonance and non-invasive left ventricular pressure: a feasibility study in left bundle branch block
Eur Heart J Cardiovasc Imaging, 21 (2), 143-153
DOI 10.1093/ehjci/jez231, PubMed 31599327
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma
Eur J Nucl Med Mol Imaging, 48 (6), 1902-1914
DOI 10.1007/s00259-020-05098-x, PubMed 33196921
Publications 2019
Amyloid-β PET-Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic
PLoS One, 14 (8), e0221365
DOI 10.1371/journal.pone.0221365, PubMed 31430334
Re: Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma
J Vasc Interv Radiol, 30 (12), 2047-2048
DOI 10.1016/j.jvir.2019.08.030, PubMed 31676203
Publications 2018
The Effect of New Formulas for Lean Body Mass on Lean-Body-Mass-Normalized SUV in Oncologic 18F-FDG PET/CT
J Nucl Med Technol, 46 (3), 253-259
DOI 10.2967/jnmt.117.204586, PubMed 29599401
Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients
Eur J Nucl Med Mol Imaging, 45 (7), 1233-1241
DOI 10.1007/s00259-018-3964-9, PubMed 29470615
Publications 2017
Respiratory motion during 90Yttrium PET contributes to underestimation of tumor dose and overestimation of normal liver tissue dose
Acta Radiol, 59 (2), 132-139
DOI 10.1177/0284185117710052, PubMed 28509566
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
J Nucl Med, 59 (4), 704-710
DOI 10.2967/jnumed.117.195347, PubMed 28848035
Combining radioiodine and external beam radiation therapy: the potential of integrated treatment planning for differentiated thyroid cancer
Acta Oncol, 56 (6), 894-897
DOI 10.1080/0284186X.2017.1286384, PubMed 28464741
Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey
EJNMMI Phys, 4 (1), 28
DOI 10.1186/s40658-017-0193-4, PubMed 29199391
Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force
EJNMMI Phys, 4 (1), 27
DOI 10.1186/s40658-017-0194-3, PubMed 29164483
Publications 2016
Short-course PET based simultaneous integrated boost for locally advanced cervical cancer
Radiat Oncol, 11, 39
DOI 10.1186/s13014-016-0612-z, PubMed 26968827
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate
J Nucl Med, 58 (1), 55-61
DOI 10.2967/jnumed.116.180471, PubMed 27587710
Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
J Nucl Med, 58 (1), 48-54
DOI 10.2967/jnumed.116.173922, PubMed 27493270
Publications 2015
New distinct compartments in the G2 phase of the cell cycle defined by the levels of γH2AX
Cell Cycle, 14 (20), 3261-9
DOI 10.1080/15384101.2015.1087617, PubMed 26317799
Publications 2014
Escherichia coli SeqA structures relocalize abruptly upon termination of origin sequestration during multifork DNA replication
PLoS One, 9 (10), e110575
DOI 10.1371/journal.pone.0110575, PubMed 25333813
How to measure CT image quality: variations in CT-numbers, uniformity and low contrast resolution for a CT quality assurance phantom
Phys Med, 30 (4), 521-6
DOI 10.1016/j.ejmp.2014.01.006, PubMed 24530005
Publications 2012
An easy-to-use simulation program demonstrates variations in bacterial cell cycle parameters depending on medium and temperature
PLoS One, 7 (2), e30981
DOI 10.1371/journal.pone.0030981, PubMed 22348034
Publications 2011
Three independent mechanisms for arrest in G2 after ionizing radiation
Cell Cycle, 10 (5), 819-29
DOI 10.4161/cc.10.5.14968, PubMed 21325885
Publications 2010
Replication patterns and organization of replication forks in Vibrio cholerae
Microbiology (Reading), 157 (Pt 3), 695-708
DOI 10.1099/mic.0.045112-0, PubMed 21163839